Literature DB >> 16869826

Rituximab-induced serum sickness.

Roger E G Schutgens1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16869826     DOI： 10.1111/j.1365-2141.2006.06214.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 2.  Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients.

Authors:  Romy Mosch; Henk-Jan Guchelaar
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

3.  Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura.

Authors:  Shoko Goto; Hiroaki Goto; Reo Tanoshima; Hiromi Kato; Hiroyuki Takahashi; Osamu Sekiguchi; Sumio Kai
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.319

4.  Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007.

Authors:  Jennifer D Peterson; Lawrence S Chan
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.